Skip to main content

Table 4 Secondary efficacy outcomes were not significantly different between patients using and not using migraine preventive medications, for all doses of lasmiditan

From: Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials

OutcomeLasmiditan dose (mg)Using preventivesNot using preventivesInteraction p-valueb
n/N (%)Odds ratioa (CI)n/N (%)Odds ratioa (CI)
Pain relief, n/N (%)PBO88/207 (42.5) 420/922 (45.6)  
5061/113 (54.0)1.5 (0.9, 2.5)292/485 (60.2)1.6 (1.3, 2.1)0.630
100109/189 (57.7)1.8 (1.2, 2.7)595/944 (63.0)2.0 (1.7, 2.5)0.712
200114/189 (60.3)2.1 (1.4, 3.1)583/931 (62.6)2.0 (1.7, 2.4)0.567
Sustained pain freedom at 24 h, n/N (%)PBO11/196 (5.6) 99/867 (11.4)  
5012/104 (11.5)1.7 (0.6, 4.4)85/452 (18.8)1.4 (1.0, 2.0)0.660
10025/175 (14.3)2.8 (1.3, 5.8)150/860 (17.4)1.6 (1.2, 2.2)0.326
20030/167 (18.0)3.7 (1.8, 7.7)192/879 (21.8)2.2 (1.7, 2.8)0.293
Total migraine freedom, n/N (%)PBO18/196 (9.2) 159/867 (18.3)  
5023/104 (22.1)3.1 (1.3, 7.4)121/452 (26.8)1.3 (1.0, 1.8)0.437
10039/175 (22.3)2.8 (1.6, 5.2)241/860 (28.0)1.7 (1.4, 2.2)0.534
20043/167 (25.7)3.4 (1.9, 6.2)287/879 (32.7)2.2 (1.7, 2.7)0.604
PGIC very much better or much better, n/N (%)PBO39/207 (18.8) 243/923 (26.3)  
5036/113 (31.9)2.0 (1.1, 3.8)183/485 (37.7)1.4 (1.1, 1.9)0.830
10062/189 (32.8)2.1 (1.3, 3.3)382/944 (40.5)1.9 (1.6, 2.3)0.830
20069/189 (36.5)2.5 (1.6, 3.9)381/931 (40.9)1.9 (1.6, 2.4)0.421
Disability-free at 2 h, n/N (%)PBO34/201 (16.9) 222/912 (24.3)  
5029/113 (25.7)1.6 (0.8, 3.2)155/480 (32.3)1.3 (1.0, 1.8)0.751
10047/189 (24.9)1.6 (1.0, 2.7)320/934 (34.3)1.6 (1.3, 2.0)0.669
20054/187 (28.9)2.0 (1.2, 3.2)327/916 (35.7)1.7 (1.4, 2.1)0.631
  1. Abbreviations: CI confidence interval, MBS most bothersome symptom, N number of patients in the subgroup of ITT population, n number of patients achieving outcome, PBO placebo, PGIC patient global impression of change
  2. aOdds ratio compared to patients who received placebo in the same subgroup
  3. bInteraction p-value comparing patients using and patients not using migraine preventive medications
\